Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma Co N.V (NAMS) Return on Sales: 2023-2025

Historic Return on Sales for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to -6.27%.

  • NewAmsterdam Pharma Co N.V's Return on Sales fell 35.00% to -6.27% in Q3 2025 from the same period last year, while for Sep 2025 it was -6.27%, marking a year-over-year decrease of 35.00%. This contributed to the annual value of -5.30% for FY2024, which is 726.00% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Return on Sales is -6.27%, which was down 142.28% from -2.59% recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's Return on Sales ranged from a high of -2.59% in Q2 2025 and a low of -33.32% during Q1 2024.
  • Its 3-year average for Return on Sales is -12.60%, with a median of -6.10% in 2024.
  • Examining YoY changes over the last 5 years, NewAmsterdam Pharma Co N.V's Return on Sales showed a top increase of 2,935bps in 2025 and a maximum decrease of 35bps in 2025.
  • NewAmsterdam Pharma Co N.V's Return on Sales (Quarterly) stood at -12.56% in 2023, then soared by 725bps to -5.30% in 2024, then plummeted by 35bps to -6.27% in 2025.
  • Its Return on Sales was -6.27% in Q3 2025, compared to -2.59% in Q2 2025 and -3.97% in Q1 2025.